SI
SI
discoversearch

 Biotech / Medical | CUBIST PHARMACEUTICALS (CBST)


Previous 10 | Next 10 
To: tuck who wrote (191)4/18/2007 4:15:48 PM
From: tuck
   of 252
 
CBST earnins in line, no guidance in PR:

>>Cubist Pharmaceuticals Reports First Quarter 2007 Results: Total Revenues $59.5 Million; Net Product Revenues $59.4 Million
Wednesday April 18, 4:01 pm ET
GAAP Basic and Diluted Net Income of $0.10 Per Share NON-GAAP Basic and Diluted Net Income of $0.15 and $0.14 Per Share, Respectively
Earnings Conference Call & Webcast Today (With Slides) at 5:00 pm EDT

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST - News) today reported results for the first quarter ended March 31, 2007. Net sales of CUBICIN® (daptomycin for injection) increased 57% from the prior year, from $37.9 million in the first quarter of 2006 to $59.4 million in the first quarter of 2007. U.S. net product revenue was $57.5 million. Total revenues for the first quarter of 2007 increased 48% over the first quarter of 2006 from $40.1 million in the first quarter of 2006 to $59.5 million in the first quarter of 2007.

Net income for the first quarter ended March 31, 2007 on a GAAP basis was $5.6 million, or $0.10 per basic and diluted share, as compared to a net loss of $5.9 million, or $0.11 per basic and diluted share for the first quarter of 2006. First quarter 2007 GAAP net income includes $2.6 million, or $0.05 and $0.04 per basic and diluted share, respectively, in stock-based compensation expenses as a result of our adoption on January 1, 2006 of Financial Accounting Standards No. 123® ("FAS 123®").

Non-GAAP net income for the first quarter ended March 31, 2007, excluding the charges mentioned above, was $8.2 million, or $0.15 and $0.14 per basic and diluted share, respectively.

As of March 31, 2007, Cubist had $320.9 million in cash, cash equivalents and investments. The total number of common shares outstanding at March 31, 2007 was 55,213,410.

Use of Non-GAAP Financial Measures

Cubist adopted FAS 123® on January 1, 2006 using the modified prospective method, which resulted in the recognition of stock-based compensation expenses in the statement of operations from 2006 onward without adjusting the prior years. Cubist uses non-GAAP net income (loss) and non-GAAP net income (loss) per share data to improve its analysis of operational results and trends. Cubist's management also uses these non-GAAP figures to make financial and operational decisions as these numbers exclude non-operational activities. These measures should not be considered an alternative to measurements required by GAAP, such as net income (loss) and net income (loss) per share, and should not be considered measures of our liquidity. A reconciliation between non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.

CONFERENCE CALL & WEBCAST INFORMATION

Cubist will host a conference call and live audio webcast to discuss its first quarter 2007

Financial results, business activities and financial outlook.

WHEN: Wednesday, April 18, 2007 at 5:00 p.m. EDT

LIVE DOMESTIC & CANADA CALL-IN: 877-407-0778

LIVE INTERNATIONAL CALL-IN: 201-689-8565

24-HOUR REPLAY DOMESTIC & CANADA: 877-660-6853

24-HOUR REPLAY INTERNATIONAL: 201-612-7415

REPLAY PASSCODES (BOTH REQUIRED FOR PLAYBACK):

ACCOUNT #: 286 CONFERENCE ID #: 229810

CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT: www.cubist.com

Replay will be available for 30 days at www.cubist.com <<

snip

The stock has been on a bit of run recently, and is up modestly after hours so far. I'm not sure why, because the only rumor I heard was for upside in EPS, and it didn't happen. Nor have we seen guidance yet. So go figure.

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: tuck who wrote (195)4/19/2007 8:22:58 PM
From: telephonics
   of 252
 
The company is now profitable and because the wall street sages guessed wrong the share p[rice gets hammered. I took advantage of this buying opportunity because I don;t think this price will around again.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


From: tuck7/19/2007 5:06:14 PM
   of 252
 
Cubicin recommended for endocarditis in the EU:

Message 23716289

Near the bottom.

Forgot about the two thread issue . . . Link to CBST's recent earnings, which were good:

Message 23712947

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read


To: telephonics who wrote (196)9/13/2007 10:39:37 AM
From: tuck
   of 252
 
>> Cubist Reveals Drug Patent Error
By Elizabeth Trotta
Staff Reporter
9/12/2007 12:18 PM EDT

URL: thestreet.com

Cubist Pharmaceuticals (CBST) said Wednesday that it found an error in a pharmaceutical composition patent, and subsequently has asked the Food and Drug Administration to delist the patent from the Orange Book, where the FDA publishes patent information on approved drug products.

The biopharmaceutical company said the technical error was related to U.S. patent No. RE39071, one of the patents for its lead product, Cubicin, an injectible antibiotic for skin infections. Specifically, the stereochemistry of an amino acid in the claimed chemical structures was incorrectly identified in the patent, which was originally issued to Eli Lilly (LLY) and is now owned by Cubist.

The error came to light while Cubist was preparing for another company's potential paragraph IV filing regarding Cubicin. Such a filing is made when another manufacturer wants to submit an abbreviated new-drug application (ANDA) for a generic version of a drug. A paragraph IV certification lists the patents that are either unenforceable or not infringed by the generic drug. The generic has to give notice of the filing to the company holding the patents in question (Cubist in this case).

Upon receiving paragraph IV certification, Cubist has 45 days to file an infringement suit. Filing a suit delays approval for 30 months, but if the company does not file the suit, the ANDA for the generic can be approved immediately.

Cubist said it will pursue the appropriate course of action in the U.S. Patent Office to correct the patent. "If and when the error is corrected, [the company] will ask FDA to re-list the corrected patent in the Orange Book," it said in a release.

After a slight drop in the morning, Cubist shares were trading up a slight 0.5% at $23.16 Wednesday. <<

One comment, which I believe is an accurate interpretation:

investorshub.advfn.com

Mr. Market is less sanguine about CBST today; it is off almost 5% as the impact of this error becomes understood. I let my shares be called away in July, but still watch.

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read


From: idos10/11/2007 4:51:42 PM
   of 252
 
An Antibiotic to the Rescue
How Cubist's Jeff Alder turned a devastating Phase III failure into an approval.
the-scientist.com

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: idos who wrote (199)10/13/2007 7:41:15 PM
From: telephonics
   of 252
 
It's a good thing he succeeded. In the Metro Washington D.C. area there have recently been a surprising number of staph skin infections among high school athletes. A number have proven to be MRSA and only cubicin can treat this scary infection.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)


To: telephonics who wrote (200)10/14/2007 3:27:19 AM
From: idos
   of 252
 
Unfortunately and ironically, Frank Tally wasn't so lucky.

Share Recommend | Keep | Reply | Mark as Last Read


To: telephonics who wrote (200)10/15/2007 9:12:41 AM
From: telephonics
   of 252
 
Where do I go to collect my prize for posting the 200th message??? And yes-Frank was unlucky and unfortunately he can't help us any more.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: telephonics who wrote (202)10/15/2007 10:42:22 AM
From: idos
   of 252
 
Zacks.com releases the list of companies likely to issue earnings surprises.

biz.yahoo.com

Cubist Pharmaceuticals (NasdaqGS: CBST - News) has topped expectations three times during the past four quarters. Ahead of the company's third-quarter report, one of the covering brokerage analysts raised his profit forecast. Although the revision was not significant enough to move the consensus estimate from 25 cents per share, it did result in a most accurate estimate of 29 cents per share. Cubist Pharmaceutical is scheduled to report on Wednesday, Oct 17, after the close of trading.
-----------------------------------------------------------------------------

"Where do I go to collect my prize for posting the 200th message?"

65 Hayden Avenue, Lexington, MA 02421, USA

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: idos who wrote (203)10/16/2007 4:29:32 PM
From: tuck
   of 252
 
CBST dips a toe in HCV waters:

>>Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
Tuesday October 16, 4:17 pm ET
Lead Compound IB657 Would Address Unmet Medical Need in HCV Infections;
Cubist Will Pay $4.7 Million for Option and Will Fund the Pivotal IND Enabling Study

LEXINGTON, Mass. & SEATTLE--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST - News) and Illumigen Biosciences, Inc. announced today that they have signed an agreement under which Cubist has an exclusive option to acquire Illumigen on terms that have been agreed to by the parties. For the option, Cubist will pay $4.7 Million and also will pay approximately $1 Million for an IND-enabling study of Illumigen's lead compound, IB657, and for Illumigen's operating costs during the option period. IB657 is a protein therapeutic in late-stage pre-clinical development as an interferon replacement product for the treatment of Hepatitis C virus (HCV) infections.

Mike Bonney, President and CEO of Cubist, said "This option provides us with an opportunity to immediately leverage our antiinfective development and regulatory expertise. The unmet medical need which IB657 would address represents a substantial market opportunity. If we exercise our option, adding an HCV compound will be an important step as we develop a pipeline behind our successful IV antibiotic CUBICIN."

Donald Elmer, Chairman of Illumigen, said "IB657 holds great promise as a therapy that may offer improved safety and efficacy when compared with current standard of care. We believe Cubist is ideally positioned to move the IB657 program forward."

If Cubist exercises its option to acquire Illumigen, Cubist will pay Illumigen shareholders $9 Million upfront and up to $75.5 Million in HCV development and regulatory milestones. If Cubist develops an Illumigen product for the treatment of viral infections other than HCV, additional development and regulatory milestone payments of up to $117 Million would apply. If Illumigen product(s) are commercialized, sales milestones of up to $140 Million as well as tiered royalties would apply.

About HCV

HCV is a virus that primarily targets the liver, currently causing infection in more than 4 million people in the US and 180 million people worldwide. The virus is difficult to eradicate, with infected patients eventually developing chronic liver infection, and, in some cases, liver cancer. HCV infection is the most common reason for liver transplantation in the US and Western Europe and the leading cause of death from liver disease.

No vaccine is currently available to prevent HCV infection. Current HCV therapy combines a pegylated-interferon with ribavirin for up to 48 weeks of treatment. Current therapy has significant problems with both safety (e.g., significant treatment limiting adverse effects and contraindications) and efficacy (e.g., 80% of HCV infections in the U.S. are due to genotype 1 virus for which the efficacy rate of current therapy is approximately 40 to 50%).

The pegylated-interferon market today is estimated to be more than $1.9Billion.

About IB657

IB657 is a late-stage pre-clinical protein therapeutic being developed as an interferon replacement. IB657 activates a key antiviral pathway downstream from the point of interferon activation. This pathway is responsible for much of the antiviral activity of interferon. IB657 does not activate the broad range of cellular functions induced by interferon. IB657 is therefore predicted to produce the antiviral activity of interferon but to have fewer side effects. The primary clinical indication targeted for IB657 is treatment of HCV infection. However, based on the proposed mechanism of action, IB657 may have therapeutic utility in the treatment of certain other viral diseases. Pre-clinical studies to assess activity against these viruses may occur in parallel with its development for HCV infection.

About Illumigen

Illumigen Biosciences, Inc. was co-founded by Drs. Charles Magness and Shawn Iadonato in 2000 to discover beneficial human genetic mutations that might provide a roadmap for novel therapeutic drug mechanisms. The discovery of IB-657 resulted from an investigation into the cause of apparent immunity to HCV infection enjoyed by people with a specific naturally occurring genetic mutation. Prior to founding Illumigen, Drs. Magness and Iadonato both were involved in the Human Genome Project. Illumigen is a privately held biopharmaceutical company based in Seattle, WA. Additional information can be found at Illumigen's web site at www.illumigen.com. <<

snip

Cheers, Tuck

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.